SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of tradipitant for motion sickness, marking the first new treatment in decades. This milestone, combined with promising Phase 2 data showing tradipitant's efficacy in reducing GLP-1 induced nausea and vomiting, has ignited widespread community discussion about its significant potential in a rapidly expanding market. Investors are also keenly anticipating upcoming regulatory decisions for other pipeline candidates, fueling speculation about substantial growth and future acquisition interest.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending due to its recent loan agreement, which aims to secure capital without immediate equity dilution, and the planned distribution of a "Dream Bowl 2026 Meme Coin" dividend tied to its Datavault AI partnership. Community sentiment is highly polarized: many foresee a significant short squeeze and value creation from tokenization and potential asset sales, while a vocal segment views these developments as further distractions by a management team perceived as eroding shareholder value. The broader context involves the company's foray into AI-driven Real-World Asset tokenization, alongside ongoing scrutiny of its core biotech pipeline.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending following the recent FDA approval of FUROSCIX for pediatric use and new patents issued for its ReadyFlow Autoinjector, which the community views as a significant advancement for at-home fluid management. While optimism surrounds these developments and the anticipated Afrezza launch in India, a persistent debate centers on current management's ability to translate product success into substantial long-term shareholder value.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid notable Bitcoin volatility and a mixed outlook driven by fluctuating ETF inflows and the impending Bank of Japan rate decision. The community is sharply divided between those anticipating a prolonged 'crypto winter' and others who see the current dips as a prime 'buy the dip' opportunity driven by continued whale accumulation and institutional interest. This divergence in sentiment underscores the ongoing debate about Bitcoin's predictable cyclical behavior versus its increasing integration into traditional finance through instruments like IBIT.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

FBTC is trending amid ongoing volatility in the Bitcoin ETF market, characterized by recent outflows followed by a modest reversal of inflows. The community remains sharply divided, with some anticipating a prolonged "crypto winter" and further declines, while others maintain a bullish long-term outlook, emphasizing Bitcoin's historical resilience against market fluctuations.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility and increased trading activity as the anticipated FDA decision for its Relacorilant treatment for Cushing's Syndrome approaches. A sharp price decline fuels community fears of potential regulatory hurdles and whispers of a Complete Response Letter, while many longs emphasize the company's robust pipeline and accuse shorts of manipulation, making its near-term outlook a major point of contention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Elon Musk’s Neuralink is reportedly exploring the use of its brain implant device to translate thoughts into text, aiming to enable people with speech impairments to communicate.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-19/musk-s-neuralink-plans-speech-trial-nonmedical-brain-implant">reported</a> on Friday that Neuralink plans to launch a clinical trial in the U.S. in October for this purpose. The company also hopes to have its device in a healthy person by 2030, the report added.&nbsp;“We’re currently envisioning a world where in about 3 to 4 years, there will be someone who’s otherwise healthy who’s going to get a Neuralink,” the company’s president, DJ Seo, said at the Korea Foundation for Advanced Studies in Seoul earlier this week, as reported by Bloomberg. Seo added that the company aims to initiate a new clinical trial to read speech from the brain, for which the U.S. Food and Drug Administration has granted it an Investigational Device Exemption.The exemption allows the company to start testing an unapproved device. Currently, there are no commercially available implants that read speech from the brain, Bloomberg noted. Neuralink is also working toward potential treatments for blindness and Parkinson’s disease, though it has yet to receive approval for any of its devices for commercial use.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.Earlier this month, Neuralink <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-s-neuralink-expands-human-trials-as-12-patients-clock-15-000-hours-on-brain-chip/chwjH1mRdtC">announced</a> that 12 people worldwide are now living with its N1 implant, collectively recording more than 15,000 hours of device use across 2,000 days. The N1 is designed for people with quadriplegia caused by spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS). Implanted through a surgical robot, the device enables users to move a computer cursor and interact with digital or physical tools solely through thought.According to Bloomberg, the company plans to implant devices in 20,000 people per year by 2031.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Neuralink logo is displayed on a mobile phone with Neuralink in the background in this photo illustration in Brussels, Belgium, on March 9, 2025. (Photo by Jonathan Raa/NurPhoto via Getty Images)

Elon Musk’s Neuralink Reportedly Plans To Translate Thoughts Into Text With Brain Implant Device

According to a Bloomberg report on Friday, Neuralink plans to launch a clinical trial in the U.S. in October for this purpose.

Equity

According to a Bloomberg report on Friday, Neuralink plans to launch a clinical trial in the U.S. in October for this purpose.


Neuralink, the brain-computer interface company founded by Elon Musk, said that 12 people around the world are now living with its N1 implant, collectively recording more than 15,000 hours of device use across 2,000 days.The update marks an expansion from June, when the company’s partner, the Barrow Neurological Institute in Phoenix, Arizona, announced that seven people with severe paralysis had received the device.&nbsp;At the time, Neuralink highlighted patients using the implant to play video games, design 3D machine parts, control robotic arms and communicate after losing speech due to amyotrophic lateral sclerosis (ALS).The N1 is designed for people with quadriplegia caused by spinal cord injuries or ALS. Implanted through a surgical robot, the device&nbsp;enables users to move a computer cursor and interact with digital or physical tools solely through thought.Neuralink also said in July that it is preparing to test its brain implant in Britain, partnering with University College London Hospitals and Newcastle Hospitals. Patients with severe paralysis will be eligible to enroll.The company raised $650 million in June to support its clinical studies. It began human trials in 2024 after addressing safety concerns raised earlier by the U.S. Food and Drug Administration, which initially rejected its application in 2022.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was ‘extremely bullish’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Elon Musk’s Neuralink Expands Human Trials As 12 Patients Clock 15,000 Hours On Brain Chip

The company also said in July that it is preparing to launch trials in Britain with top hospitals, expanding eligibility to patients with severe paralysis.

OpenAI and co-founder Sam Altman are reportedly set to back a startup that would compete with Elon Musk’s Neuralink.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/04484164-724e-4fc2-92a2-e2c13ea639bd?FTCamp&amp;#61;engage/">report</a> by the Financial Times, the company in question is Merge Labs. It is seeking funds at an $850 million valuation, with OpenAI’s ventures team expected to provide the bulk of the capital.&nbsp;While Altman will not be personally investing in the company, he will be one of the co-founders, the report stated. However, it added that he may not be involved in the new entity’s day-to-day operations.&nbsp;Insiders told the publication that Altman supports the investment. The report said that the OpenAI CEO plans to launch the project alongside Alex Bania, who runs World, a retina-scanning digital ID project, which Altman also backs.It noted that the new startup aims to build brain-computer interfaces, which would put it in direct competition against Musk’s Neuralink. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OPENAI">OpenAI</a> was in ‘extremely bullish’ territory, while retail sentiment around Musk’s <a href="https://stocktwits.com/symbol/NEURALINK">Neuralink</a> was in the ‘extremely bearish’ zone.The two billionaires have already&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/sam-altman-fires-back-at-elon-musk-over-apples-chatgpt-favoritism-claims/chrDUplRd7g">been at odds</a> of late, with Musk claiming on Monday that Apple (AAP) was biased toward OpenAI, making it “impossible” for other AI apps like xAI’s Grok to move up in the App Store’s rankings.&nbsp;"Apple is behaving in a manner that makes it impossible for any AI company besides OpenAI to reach #1 in the App Store, which is an unequivocal antitrust violation," Musk wrote on X. "XAI will take immediate legal action." xAI's Grok app currently sits in fifth position on the Apple App Store's top free apps chart, four spots away from ChatGPT. Retail sentiment on Stocktwits around <a href="https://stocktwits.com/symbol/XAI">xAI</a> was in 'bullish' territory at the time of writing.The pair co-founded OpenAI, though Musk exited the board in 2018 following disputes with Altman. The split sparked a bitter rivalry between the two as they fight for leadership in AI.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-tells-goldman-ceo-david-solomon-to-focus-on-being-a-dj/chrx4DMRdJg">Trump Tells Goldman CEO David Solomon To ‘Focus On Being a DJ’ Over ‘Bad’ Tariff Predictions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of 'OpenAI' is displayed on a mobile phone with the photographs of Elon Musk and Sam Altman in Ankara, Turkiye on March 14, 2024. (Photo by Muhammed Selim Korkutata/Anadolu via Getty Images)

Musk–Altman Battle Heats Up With OpenAI’s Reported $850M Bet On Neuralink Competitor

OpenAI’s ventures team is expected to contribute the bulk of the financing in Merge Labs’ $850 million valuation round, the Financial Times said.

NEURALINK
Neuralink Corp.

Latest NEURALINK News

NEURALINKNeuralink Corp.

Latest NEURALINK News

NEURALINK
Neuralink Corp.